NUVL Nuvalent Inc

$76.08

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending
Expected on
Report Time: Unknown Release Time
The Whisper Number
Consensus Estimate:
Revenue Estimate:

Latest Earnings Insight

Updated On 8/22/2025

About Nuvalent Inc

No Company Description Available

Website: N/A

Sector
LIFE SCIENCES
Industry
PHARMACEUTICAL PREPARATIONS
Exchange
NASDAQ
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1861560
Address
ONE BROADWAY, 14TH FLOOR, CAMBRIDGE, MA, US
Valuation
Market Cap
$5.13B
P/E Ratio
nan
PEG Ratio
nan
Price to Book
4.79
Performance
EPS
$-3.93
Dividend Yield
Profit Margin
0.00%
ROE
-29.50%
Technicals
50D MA
$74.07
200D MA
$83.87
52W High
$113.51
52W Low
$55.53
Fundamentals
Shares Outstanding
66M
Target Price
$111.70
Beta
1.43

NUVL EPS Estimates vs Actual

Estimated
Actual

NUVL News & Sentiment

Aug 19, 2025 • Benzinga SOMEWHAT-BULLISH
This Thermo Fisher Scientific Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - AeroVironment ( NASDAQ:AVAV ) , Celestica ( NYSE:CLS )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.
Aug 07, 2025 • Motley Fool NEUTRAL
Nuvalent ( NUVL ) Q2 R&D Up 65%
Nuvalent ( NASDAQ:NUVL ) , a clinical-stage biotechnology company developing therapies for cancers driven by kinase mutations, released its second quarter 2025 earnings results on August 7, 2025. There was no product revenue, consistent with expectations for a pre-commercial biotech.
Jun 24, 2025 • Benzinga NEUTRAL
Nuvalent Touts 'Positive' Data From Lung Cancer Drug Trial - Nuvalent ( NASDAQ:NUVL )
Zidesamtinib achieves a 51% ORR and 93% 12- and 18-month durability in patients with one prior ROS1 TKI. Intracranial ORR is 85% in patients previously treated with crizotinib, including 54% complete responses.
Feb 24, 2025 • GlobeNewswire SOMEWHAT-BULLISH
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer
WELLESLEY HILLS, Mass., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. ( Nasdaq: CLYM ) announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry.
Feb 24, 2025 • Benzinga SOMEWHAT-BULLISH
Climb Bio Appoints Perrin Wilson, Ph.D., as Chief Business Officer - Climb Bio ( NASDAQ:CLYM )
WELLESLEY HILLS, Mass., Feb. 24, 2025 ( GLOBE NEWSWIRE ) -- Climb Bio, Inc. CLYM announced today the appointment of Perrin Wilson, Ph.D. as Chief Business Officer. Dr. Wilson is an accomplished leader, with over 17 years of experience in the pharmaceutical and biotech industry.
Dec 30, 2024 • Benzinga SOMEWHAT-BULLISH
This Nuvalent Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday - Arcutis Biotherapeutics ( NASDAQ:ARQT ) , Artiva Biotherapeutics ( NASDAQ:ARTV )
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. HC Wainwright & Co. analyst Ed Arce initiated coverage on MetaVia MTVA with a Buy rating and announced a ...
Sentiment Snapshot

Average Sentiment Score:

0.233
50 articles with scored sentiment

Overall Sentiment:

Bullish

NUVL Reported Earnings

Feb 27, 2025
Dec 31, 2024 (Pre market)
-0.0 Surprise
  • Reported EPS: $-1.05
  • Estimate: $-1.05
  • Whisper:
  • Surprise %: -0.0%
Nov 12, 2024
Sep 30, 2024 (Pre market)
-0.39 Surprise
  • Reported EPS: $-1.28
  • Estimate: $-0.89
  • Whisper:
  • Surprise %: -44.2%
Aug 08, 2024
Jun 30, 2024 (Pre market)
-0.14 Surprise
  • Reported EPS: $-0.88
  • Estimate: $-0.74
  • Whisper:
  • Surprise %: -19.2%
May 09, 2024
Mar 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.69
  • Estimate: $-0.68
  • Whisper:
  • Surprise %: -1.5%
Feb 27, 2024
Dec 31, 2023 (Pre market)
-0.02 Surprise
  • Reported EPS: $-0.62
  • Estimate: $-0.60
  • Whisper:
  • Surprise %: -3.3%
Nov 14, 2023
Sep 30, 2023 (Pre market)
-0.01 Surprise
  • Reported EPS: $-0.59
  • Estimate: $-0.58
  • Whisper:
  • Surprise %: -1.7%
Aug 10, 2023
Jun 30, 2023 (Pre market)
0.02 Surprise
  • Reported EPS: $-0.51
  • Estimate: $-0.53
  • Whisper:
  • Surprise %: 3.8%
May 11, 2023
Mar 31, 2023 (Pre market)
0.07 Surprise
  • Reported EPS: $-0.44
  • Estimate: $-0.51
  • Whisper:
  • Surprise %: 13.7%
Mar 16, 2023
Dec 31, 2022 (Pre market)
-0.06 Surprise
  • Reported EPS: $-0.49
  • Estimate: $-0.43
  • Whisper:
  • Surprise %: -13.9%

Financials